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Neuroimaging is central to the quest for a biological foundation of psychiatric diagnosis but so far has not
yielded clinically relevant biomarkers for mental disorders. This review addresses potential reasons for
this limitation and discusses refinements of paradigms and analytic techniques thatmay yield improved diag-
nostic and prognostic accuracy. Neuroimaging can also be used to probe genetically defined biological path-
ways underlying mental disorders, for example through the genetic imaging of variants discovered in
genome-wide association studies. These approaches may ultimately reveal mechanisms through which
genes contribute to psychiatric symptoms and how pharmacological and psychological interventions exert
their effects.The demonstration, in 1976, that patients with schizophrenia had
enlarged cerebral ventricles (Johnstone et al., 1976), seemed to
usher psychiatry into a new era where neuroimaging would help
identify mental disorders and ultimately clarify their mechanisms.
In the cultural climate of the 1970s, such claims of tangible bio-
logical signsmay have perturbed those who believed that mental
disorders were the product of early life experience and other bio-
graphical influences. In the past 35 years, modern psychiatry has
largely overcome such dualisms, and there is now general agree-
ment that environmental influences can manifest themselves in
observable brain changes as well as genetic factors. Perhaps
the most remarkable result of this rapprochement between
psychological and biological approaches to mental illness is
the emergence of research programs mapping out neural corre-
lates and predictors of psychotherapy successfully with func-
tional neuroimaging (Beutel et al., 2003; DeRubeis et al., 2008;
Kandel, 1999; Linden, 2006, 2008; Roffman et al., 2005).
Another important development has come out of the growing
dissatisfaction with current diagnostic systems in psychiatry.
Although the authors of the Diagnostic and Statistical Manual
of Mental Disorders (DSM) (American Psychiatric Association,
2000) and the International Classification of Disease (World
Health Organisation, 1992) were guided by the aim to make the
diagnostic criteria more reliable, these criteria are still largely
based on clinicians’ assessments. Thus, patients whose symp-
toms are caused by very different biological processes may be
subsumed under the same category, and some of them may
receive inappropriate treatment as a consequence. In order to
improve this situation, it has been suggested that the new
DSM-5 incorporate etiological criteria. Yet reliable etiological
models and biomarkers are currently not available for most
psychiatric disorders, and even further clinical subtyping has
not made the association with biological markers more stringent.
Psychiatric diagnosis will thus continue to be based on descrip-
tive criteria for the foreseeable future (First, 2010).
Neuroimaging in its various guises is likely to play a major
role in the quest for a biological foundation of psychiatric8 Neuron 73, January 12, 2012 ª2012 Elsevier Inc.diagnoses, if only because it is the only array of techniques
that routinely provides direct access to the living human brain
(Table 1). Imaging can complement clinical trials in phases
0/I/II to determine in vivo effects of drugs and appropriate
dosages, and in phases III/IV for treatment monitoring and
stratification of patient samples and flexible dose adjustment
over time.
The State of Biomarker Development for Mental
Disorders
A biomarker has been defined as a ‘‘characteristic that is
objectively measured and evaluated as an indicator of normal
biological processes, pathogenic processes, or pharmacologic
responses to a therapeutic intervention’’ (Biomarkers Definitions
Working Group, 2001). Biomarkers that indicate the presence of
a disease can be used for diagnostic purposes, classification, or
staging of disease or for the prediction of the course of the
illness. Such prognostic biomarkers may be particularly useful
if they predict the future occurrence of an illness in preclinical
cases. In the context of clinical trials, biomarkers can be used
for ‘‘proof of concept’’ where they indicate that an intervention
affects disease-relevant pathological processes (Soares,
2010). Another use of biomarkers is for ‘‘proof of mechanism’’
where it is demonstrated that an intervention affects the desired
biological process. A major application is to show that a drug
engages with a target in vivo in the way expected from in vitro
studies. Where the effects of a therapeutic intervention on the
biomarker predict the desired clinical outcome, the biomarker
could even be taken forward as a potential surrogate marker.
A validated surrogate marker, which has to undergo approval
according to strict criteria (Cummings, 2010), could permit
a reduction of the participant numbers and duration needed to
demonstrate clinically relevant effects (Hampel et al., 2011;
Jagust et al., 2010).
Imaging biomarkers have been relatively successful in the field
of neurodegenerative disorders. PET with 18F-fluorodeoxyglu-
cose (FDG) distinguishes Alzheimer’s disease (AD) from other
Table 1. Comparison of Noninvasive Neuroimaging Modalities in Biomarker Research
Technique Spatial Resolution
Temporal
Resolution
Sensitivity to
Specific Molecules Retest-Reliability
Suitability for Multicenter
Studies References
Structural magnetic
resonance imaging
(MRI)
Millimeter, in some
cases (ultra-high
field) submillimeter
Can be used
to track
longitudinal
changes
None, but can
study effects of
pharmacological
intervention or genes
Good within scanners,
moderate across scanners
of the same type, poor
across magnet field
strengths
Yes if magnet of same field
strength and rigorous
protocol design / calibration /
quality control
Reliability: Kruggel
et al., 2010
Functional MRI (fMRI) Millimeter Seconds See under
structural MRI
Blood oxygen level-dependent
signal (BOLD) activation
studies: needs to be
determined for each
paradigm; published
reports go up to 0.8;
perfusion studies: high
Under development; requires
scanners of same field
strength and well
standardized paradigms
Reliability: Blokland
et al., 2011; Xu et al., 2010.
Multicenter: Barch and
Mathalon, 2011
Magnetic resonance
spectroscopy (MRS)
Centimeter Minutes Millimolar Reported as good for some
brain regions and metabolites,
optimized procedures for
neurotransmitters (GABA,
Glutamate/Glutamine)
under development
Under development; for
example, guidelines have
been proposed for
multiple sclerosis
Reliability: Geramita et al.,
2011. Multicenter:
De Stefano et al., 2007
Positron emission
tomography (PET)/
single photon
emission computed
tomography (SPECT)
Centimeter (SPECT)
to millimeter (PET)
Minutes Picomolar Needs to be determined for
each ligand and region;
for example reports for
raclopride range from
moderate to good
Standardization procedures
have been developed,
for example for FDG-PET
in clinical trials of AD
Reliability: Alakurtti
et al., 2011; Yoder et al.,
2011. Multicenter:
Jagust et al., 2010
Magnetoencephalography
(MEG)
Centimeter Milliseconds See under
structural MRI
Needs to be determined for
each paradigm and parameter;
for example, high for visual
gamma activity
Under development Reliability:
Muthukumaraswamy
et al., 2010. Multicenter:
Gaetz et al., 2011
Electroencephalography
(EEG) / event-related
potentials (ERP)
Centimeter Milliseconds See under
structural MRI
Depends on paradigm,
high for P300 ERP in
oddball studies
Quality assurance and
standardization procedures
under development
Reliability and multicenter:
Luck et al., 2011
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Reviewdementias (frontotemporal dementia and dementia with Lewy
bodies) with high classification accuracy (Mosconi et al., 2010).
FDG-PET has also shown promise in predicting future AD in
people with mild cognitive impairment (MCI) and even in
cognitively normal individuals (Mosconi et al., 2010). Imaging
biomarkers have also been used for proof-of-concept in the
evaluation of new interventions for dementia. For example,
FDG-PET has been used to demonstrate partial reversal of defi-
cits in glucose metabolism in AD in a phase I trial of deep-brain
stimulation (Laxton et al., 2010). Amyloid imaging with PET can
be used for the proof-of-concept and -mechanism of interven-
tions that modify amyloid pathology through blockade of amyloi-
dogenic enzymes or immunization (Scheinin et al., 2011).
Although neither neuroimaging nor neurochemical biomarkers
have thus far attained the status of approved surrogate end
points for clinical trials in AD or MCI (Hampel et al., 2010), their
predictive value may give them a place in clinical trials of MCI
where they can enrich the trial population with individuals
affected by the AD-related pathological process (Cummings,
2010).
Compared to the wide spectrum of neuroimaging biomarker
applications in dementia research, biomarker use in psychotic
or affective disorders has been largely confined to the proof of
mechanism of new drugs. Radioligands for the targets of the
drug (commonly neurotransmitter receptors or transporters)
can be used to measure target occupancy and help determine
what doses are needed for a desired level of occupancy. This
approach has been particularly widely used in the investigation
of dopamine receptor occupancy of antipsychotic drugs (Nord
and Farde, 2011) and of serotonin transporter blockade of anti-
depressants (Meyer, 2007). Recent work has demonstrated
a correlation between dopamine D2 receptor occupancy and
clinical improvement after treatment with the antipsychotics
aripiprazole (Kegeles et al., 2008) and quetiapine (Nikisch
et al., 2010), but patient numbers, as in most PET studies,
were small. Radioligands are also available for other potential
targets of new antipsychotics, for example cannabinoid, tachyki-
nin, glutamate, and nicotinic acetylcholine receptors (Takano,
2010) (Table 2). Such proof-of-mechanism studies can be useful
both for the identification and rejection of new drugs (Wong et al.,
2009). However, only a limited number of receptor subtypes or
binding sites can be targeted, and often they do not include
those that are of greatest current clinical interest (for example,
the glycine and D-serine binding sites on the NMDA [N-methyl-
D-aspartate]-type glutamate receptor; Takano, 2010). Moreover,
almost all current targets are membrane proteins (see Table 2)
and the postsynaptic signaling cascades, which are presumed
to be of crucial relevance to the neural mechanisms of psychosis,
depression, and addiction, for example (Kleppisch and Feil,
2009; Nestler et al., 2009; Wolf and Linden, 2011), are largely
inaccessible to in vivo molecular imaging. Nevertheless, neuroi-
maging with radioligands andMRI techniques, particularly MRS,
have a place in the evaluation of the pharmacokinetics and phar-
macodynamics of new psychotropic drugs (Wong et al., 2009).
The progress with diagnostic or prognostic imaging bio-
markers of mental disorders has been comparatively disap-
pointing. For example, a recent study confirmed the specificity
of ventricular enlargement for schizophrenia compared to affec-10 Neuron 73, January 12, 2012 ª2012 Elsevier Inc.tive psychosis. However, this study suggested that relatives of
patients with familial schizophrenia (that is, with at least two
known cases in the family) may also show this sign (McDonald
et al., 2006). Thus, ventricle enlargement may be associated
with the genetic risk of schizophrenia rather than the actual mani-
festation of the disease. Furthermore, the general problem with
structural imaging findings in schizophrenia is that even where
significant group differences have been reliably documented,
the overlap with the healthy population is too large to allow for
a diagnostic use. Structural imaging studies of white matter
using diffusion tensor imaging (DTI) consistently report changes
(smaller volume, lower fractional anisotropy) in the corpus
callosum (Rotarska-Jagiela et al., 2008), even in untreated
patients (Venkatasubramanian et al., 2010), but again the overlap
with the healthy population is considerable. The same is true for
the neurophysiological signatures of altered perceptual and
cognitive processing in schizophrenia (Haenschel and Linden,
2011) or fMRI measures of connectivity of resting state networks
(Greicius, 2008), none of which has attained biomarker status.
One reason for the failure, so far, of structural and neurophys-
iological measures to produce biomarkers of mental disorders
might be that they lack the neurochemical specificity that is
needed to detect a disease characterized by altered neurotrans-
mitter or receptor function. Based on this rationale, SPECT or
PET should be more successful, particularly in schizophrenia,
where the treatment effects of antidopaminergic drugs point to
an important role of the dopamine system. However, these
techniques have so far not produced imaging biomarkers of
schizophrenia either (Nikolaus et al., 2009). For example, the
decrease of dopamine receptor occupancy after amphetamine
challenge (interpreted as increased responsiveness of presyn-
aptic dopamine release) (Abi-Dargham et al., 1998; Laruelle
et al., 1996) shows too much overlap with the healthy population
to allow for use as biomarker. Furthermore, patients with
schizotypal personality disorder have similar changes (Abi-
Dargham et al., 2004). Another key measure is the striatal uptake
of 18F-DOPA (dihydroxyphenylalanine), thought to reflect dopa-
mine synthesis. The majority of studies in schizophrenia, partic-
ularly with patients in the acute phase of the illness, did indeed
show increased uptake (Nikolaus et al., 2009; Urban and Abi-
Dargham, 2010). However, a recent study did not find any differ-
ences between stable treated patients, unaffected twins, and
controls (Shotbolt et al., 2011). The authors suggested that
increased striatal 18F-DOPA uptake may be a state marker of
acute psychosis, which would vary over time andwith treatment,
rather than a vulnerability marker, which should be relatively
stable over time.
The ideal biomarker has high diagnostic specificity and sensi-
tivity and/or is a good predictor of outcome. It is therefore impor-
tant to search for imaging parameters that show high variability
between the clinical phenotypes of interest (e.g., diagnostic
groups or treatment effects) but should not be influenced by
random variability produced by differences in imaging hardware
or software or by intraindividual variability that is not related to
the clinical state. Although imaging methods are being devel-
oped to the standard required for biomarker research (Table 1),
at the present time there does not appear to be a single neuro-
imaging parameter of biomarker quality to distinguish patients
Table 2. Important Molecular Targets of Noninvasive Imaging in the Human Brain
Biological System and Imaging Techniques Specific Subsystem Targeted Specific Target Molecules
NT Receptors (PET/ SPECT) dopamine D1,2,3 receptors
serotonin 5-HT1A, 1B, 2A receptors
glutamate Metabotropic glutamate receptor 5; NMDA receptor
histamine H1, H3 receptors
tachykinins Neurokinin 1 receptor
adenosine A1, A2A receptors
acetylcholine Alpha4beta2 and Alpha7 subunits of nicotinic receptor;
muscarinic receptor
opioids Mu, kappa, delta receptors
cannabinoids CB1 receptor
GABA (gamma-aminobutyric acid) GABA-A receptor (benzodiazepine binding site
and Alpha5 subunit)
Sigma receptor
NT Transporter (PET/ SPECT) monoamines Dopamine transporter; Vesicular monoamine
transporter 2; serotonin transporter;
norepinephrine transporter
NT Synthesis (PET/ SPECT, MRS) monoamines Aromatic amino acid decarboxylase
GABA
glutamate / glutamine
NT Metabolism (PET/ SPECT) monoamines Monoamine oxidase
acetylcholine Acetylcholine esterase
Butyrylcholine esterase
General metabolism (PET) glucose uptake
oxygen metabolism, blood flow
Inflammation (PET) microglia Translocator protein (18kDa)
Neurodegeneration (PET) extracellular changes Amyloid plaques
intracellular changes Neurofibrillary tangles
Postsynaptic signaling and neuronal
metabolism (MRS)
N-acetyl aspartate, myo-inositol
Drug metabolism (PET) blood brain barrier / efflux transporters P-glycoprotein
Sources: Molecular Imaging and Contrast Agent Database (MICAD), accessed on 27 November 2011 at http://www.ncbi.nlm.nih.gov/books/
NBK5330/, and Nikolaus et al., 2009; Takano, 2010; Wong et al., 2009.
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Reviewwith a particular mental disorder from controls (let alone to distin-
guish between different mental disorders, which is arguably the
clinically more relevant question). In the following sections I will
discuss some fruitful avenues for identifying reliable biomarkers
and the challenges inherent in these promising approaches.
Pattern Classification
Promise and Caveats
If single neuroimaging parameters have largely failed the
biomarker test, perhaps combining different measures either
from a single or several imaging modalities in a multivariate anal-
ysis will yield higher diagnostic accuracy. The basic idea behind
the pattern classification approaches in neuroimaging is that the
key differences between groups (e.g., patient versus control) or
states (e.g., symptomatic versus remitted) may lie in the relation-
ship between different parameters, for example the relative acti-
vation levels in different areas of the brain. Most neuroimaging
pattern classification studies start from a very large number offeatures, up to the hundreds of thousands of voxels that can
be captured in high resolution experiments (feature extraction,
see Figure 1). These data are fed into a classifier algorithm, for
example a support vector machine (SVM). This algorithm then
finds the optimal separation between the two or more classes
in question (task conditions or diagnostic groups).
Classifiers can be trained to any level of accuracy, but their
predictive performance will vary based on the quality of the
data and the number of parameters needed. The accuracy of
the prediction needs to be tested on new cases that are different
from the training set. The classifier assigns a label to each of the
new cases, for example ‘‘group 1’’ versus ‘‘group 2’’ (Figure 1),
and these labels are compared with the ‘‘real’’ diagnosis or
a known outcome. With the small sample sizes used in MVPA
classification studies thus far, this has commonly been achieved
with cross-validation procedures such as the ‘‘leave one out
procedure,’’ where the classifier is trained on all cases but one
and then tested for accurate classification of the remainingNeuron 73, January 12, 2012 ª2012 Elsevier Inc. 11
Figure 1. Flowchart of MVPA of Brain Imaging Data for Diagnostic Classification
Brain imaging data are obtained from two ormore diagnostic groups and relevant features extracted, as in standard univariate analysis. Because data reduction is
crucial to the success of this procedure, various strategies for feature selection can be performed, including principal components analysis (PCA) and iterative
elimination of nondiscriminating features through recursive feature elimination (RFE) (De Martino et al., 2008). The preselected data are then fed into a classifier
algorithm, which finds the optimal boundary between the two groups (e.g., the data points from the ‘‘red’’ and ‘‘green’’ groups in the right lower corner, figure
panel courtesy of Professor Rainer Goebel, Maastricht University). The approach is similar with higher numbers of features, except that hyperplanes rather than
lines will constitute the decision boundaries. The performance of the trained classifier then has to be tested in independent data. Even a good performance on
cross-validation does not imply clinical relevance because the effects may be platform specific. An important pragmatic stage is therefore the testing of the
classifier predictions in completely independent samples from other imaging centers, ideally even with slightly altered measurement parameters to test
robustness.
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Reviewcase. However, testing the classifier on a completely indepen-
dent (‘‘hold out’’) data set is recommended in order to more
robustly estimate the expected accuracy in real-life situations
of clinical diagnosis or prognosis, where class membership is
not a priori known.
Most diagnostic studies with multivoxel pattern analysis
(MVPA) have been based on structural imaging and some have
obtained classification accuracies around 90% (Table 3).
Although at such levels of accuracy, MVPA analysis of structural
scans may in principle aid clinical diagnosis, accurately classi-
fying psychiatric disease in patients suffering manifest clinical12 Neuron 73, January 12, 2012 ª2012 Elsevier Inc.symptoms is perhaps not the greatest challenge of psychiatry.
A real clinical benefit might be derived from the early detection
of cases at high risk and the prediction of natural history and
treatment outcome. Koutsouleris et al. (2009) tested patients
with prodromal symptoms of schizophrenia and obtained classi-
fication accuracies over 80% with whole-brain gray matter
patterns between controls, early and late psychosis-risk states,
as well as prediction of conversion to psychotic disorder. The
effectiveness of medication in preventing psychiatric disease
even in psychologically well-defined high-risk groups (such as
prodromal patients for schizophrenia or MCI for AD) is still not
Table 3. Classification Accuracies of Selected Structural Brain Imaging Studies Employing Multivariate Analyses to Classify Patient
Groups
Group Discrimination Imaging Parameter Sensitivity Specificity Accuracy References
AD versus normal aging Whole-brain gray matter morphometry 60.6–100 80–95 81.1–96.4* Klo¨ppel et al., 2008
AD versus FTD Whole-brain gray matter morphometry 83.3 94.7 89.2 Klo¨ppel et al., 2008
MCI versus normal aging Shape of hippocampus 83% 84% 83% Gerardin et al., 2009
SZ versus HC Whole brain morphometry 73.9% 87.3% 81.1% Davatzikos et al., 2005
Adults with ASD versus HC Whole-brain gray matter morphometry 60% (RH) /
90% (LH)
70% (RH) /
80% (LH)
65% (RH) /
85% (LH)
Ecker et al., 2010
FXS versus controls Whole-brain gray matter morphometry 96.1% 89.6% 92.9% Hoeft et al., 2008
AD: Alzheimer’s disease; ASD: autism spectrum disorder; FTD: frontotemporal dementia; FXS: fragile-X syndrome; HC: healthy controls: LH: left
hemisphere; MCI: mild cognitive impairment; RH: right hemisphere; SZ: schizophrenia. *For analyses of different subgroups.
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imaging would greatly aid clinical trials aimed at developing
drugs that could be administered prophylactically in individuals
with the highest risk. The prediction accuracies obtained by
Koutsouleris et al. (2009) were in the upper range of those
reported for purely clinical predictors (Klosterko¨tter et al.,
2011), but a formal evaluation whether imaging biomarkers
provide added value to clinical and psychometric predictors of
psychosis is still lacking.
Gray matter volumetry is not the only parameter that has been
utilized for such diagnostic and predictive purposes. Using DTI,
Ingalhalikar et al. (2010) obtained high classification accuracy for
schizophrenia in adults and for ASD in children. Similarly, Rathi
et al. (2010) applied this method for early detection of first
episode psychosis in schizophrenia. fMRI has also been used,
particularly in depression, both during the resting state (Crad-
dock et al., 2009) and during presentation of emotional facial
expressions (Fu et al., 2008).
Although the classification accuracy of MVPA techniques has
been high in several studies, they may not reveal much about the
underlying neurobiology of the disorder. Themutual dependence
of signal from different voxels often prevents simple neuroana-
tomical interpretations. However, the feature maps may provide
some indication of which neuroanatomical correlates are partic-
ularly relevant for the diagnosis in question. For example, the
patients with fragile X syndrome (FXS) showed a distinctive
pattern of volume increases (basal ganglia) and decreases
(frontal lobe) (Hoeft et al., 2008), and the late prodromal group
showed relative gray matter decrease in many cortical areas
but also increases in other areas including the thalamus (Kout-
souleris et al., 2009). In the same study, those who would later
develop schizophrenia (‘‘converters’’) could be distinguished
from the nonconverters on the basis of smaller gray matter
volume mainly in limbic and temporal areas. These findings
may support biological models positing progressive cortical
volume loss as a risk factor for schizophrenia (Wood et al., 2008).
Biomarkers derived from pattern classification do not come
with clear cut-off points and depend strongly on the experi-
mental parameters (e.g., numbers of scanned voxels) and
analytical approches (e.g., the algorithm used for feature selec-
tion), and their practical relevance therefore needs to be demon-
strated in multicenter studies, where the prediction accuracy of
a template derived from one scanner is tested in data setsfrom others (Klo¨ppel et al., 2008). Such confirmation in indepen-
dent test samples is also needed to overcome doubts about the
prediction estimates obtained through cross-validation in small
samples (Isaksson et al., 2008). However, based on the prom-
ising results obtained so far, it can reasonably be expected
that pattern classification of brain imaging data, in combination
with clinical and psychometric data, will improve our ability to
predict the course of psychiatric diseases.
Reliability and Publication Bias
Although the reliability of structural imaging measures is high on
the same scanner, it is insufficient when tested across scanners
(Kruggel et al., 2010). However, improvements are to be ex-
pected from wider use of high-field scanners with better image
quality and segmentation results. Replication is also likely to
be better if at least the field strength is kept constant across
sites. The successful discrimination of AD patients from controls
in a multicenter study of structural imaging data is promising in
this respect (Klo¨ppel et al., 2008). Less information is available
about the reliability of specific functional imaging measures,
because these would in principle have to be computed for
each individual cognitive paradigm. The literature on reproduc-
ibility of task-related activation converges to report consistency
in the qualitative activation patterns, but considerable intraindi-
vidual variability, across scanning sessions (Gountouna et al.,
2010) (Table 1). We are thus still far away from fMRI-based
biomarkers at the individual level. The situation is similar for
resting state measures, which have been too heterogeneous
across individuals to allow for the development of stable
biomarkers of disease (Greicius, 2008). However, recent work
on graph theoretical metrics of functional connectivity has
yielded promising results for the intraindividual reliability of
some metrics (Braun et al., 2012). A first step toward the
development of biomarkers from resting state activation
metrics would thus be to achieve agreement on standardized
analysis procedures based on the measures with the highest
reproducibility.
Because most neuroimaging studies still have relatively low
numbers (up to 20 for PET, up to 100 for MRI), multicenter
studies or meta-analyses are considered to be important ways
of increasing the confidence in imaging findings. One problem
with meta-analyses, which may not be confined to the field of
neuroimaging (Ioannidis, 2005), is the potential overrepresenta-
tion of positive findings in the published literature. A recentNeuron 73, January 12, 2012 ª2012 Elsevier Inc. 13
Figure 2. A Highly Simplified Model of the Genetic Pathways in Polygenic Psychiatric Diseases, Using the Examples of Schizophrenia and
Bipolar Disorder
The multiple genetic variants that can contribute to the clinical phenotype (Genes 1.) are likely to operate through a smaller number of intermediate biological
pathways (a.), and not all of them may need to be altered to affect the respective pathway. One gene can contribute to multiple pathways (as in the case of
hypothetical gene 2), and both genes and pathways can contribute to more than one disorder, resulting in the genetic overlap between schizophrenia,
schizoaffective disorder and bipolar disorder. Genes can interact with each other andwith environmental factors. The effects of the altered biological pathways on
brain structure and function result in neuroimaging phenotypes, which can reflect the underlying genetic/biological processes more sensitively and specifically
than the clinical phenotypes. Only a subset of genetic variants would be present in each case of psychosis, and their number and effect strengths would
determine individual genetic risk. The examples of the ZNF804A (Esslinger et al., 2009a) and CACNA1C (Erk et al., 2010) variants are discussed in the text.
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psychiatric disorders reported evidence for a considerable over-
reporting of significant group differences (except for the cerebral
ventricles) (Ioannidis, 2011). Potential reasons include publica-
tion bias, selective reporting of brain regions showing group
differences, and other arbitrary decisions that can be summarily
termed ‘‘researcher degrees of freedom’’ (Simmons et al., 2011).
However, the evaluation by Ioannidis (2011) did not include
whole-brain volumetric studies that implement whole-brain
correction for multiple comparisons, which should be less
vulnerable to the selective reporting bias. Suggested improve-
ments included the increase of power through multicenter
studies, preregistration of clinical imaging studies, and definition
of standardized analysis protocols (Ioannidis, 2011).
Genetic Imaging
Refining Molecular Methods
Clinical phenotypes in mental disorders may just be the
endpoints of multiple converging pathophysiological pathways
that are triggered by different combinations of genetic predispo-
sition and environmental stress (Figure 2). As such, one way of
improving the consistency of imaging findings in psychiatry14 Neuron 73, January 12, 2012 ª2012 Elsevier Inc.may be to probe the biological pathways implicated in specific
mental disorders. Current genetic models posit that multiple
common variants with small effects or rare variants with larger
effects confer the genetic vulnerability to psychotic disorders
(Owen et al., 2010). Studies on patient samples that are not
further differentiated by genotype may therefore obscure
specific biological effects, whereas it may be possible to
elucidate pathways to the disorder (Meyer-Lindenberg, 2010)
through the effects of the risk variants on parameters of struc-
tural or functional neuroimaging, radioligand binding, or noninva-
sive neurophysiology. A particularly attractive aspect of this
approach is that, in principle, it allows targeting any protein for
which a functionally relevant genetic variant exists and would
thus greatly expand the list of molecular mechanisms that can
be investigated with neuroimaging (Table 2). It may also help
overcome the lack of cellular resolution of current non-invasive
neuroimaging techniques. Although high-resolution MRI at 7
Tesla can resolve the laminar structure of human cortex
(Sa´nchez-Panchuelo et al., 2011), each layer contains amultitude
of functionally and structurally diverse neurons that cannot be
differentiated. Such differentiation of neurons within an area
may be particularly relevant for psychiatric disorders, for
Neuron
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and GABAergic interneurons in prefrontal cortex (Lewis and
Lieberman, 2000) or between medium spiny neurons expressing
dopamine D1 or D2 receptors in the striatum (Lovinger, 2010;
Moore et al., 1999). Although some information about specific
molecular pathways may be obtained through combination of
neuroimaging with pharmacological intervention, this is
approach is limited by the availability of psychotropic agents
that are approved for use in humans, and by the pleiotropic
effects ofmost drugs. Genetic variants affecting specific compo-
nents of a signaling pathway, for example transporters, recep-
tors, metabolising enzymes, and postsynaptic proteins, may
thus allow for a more fine grained dissection of its effects on
brain and behavior (Bilder et al., 2004; Frank and Fossella, 2011).
Most work in noninvasive genetic neuroimaging has so far
probed the effect of single genetic variants that appeared prom-
ising because of their neurochemical effects or their association
with a clinical phenotype. Variants defined by a single-nucleotide
change are referred to as ‘‘single-nucleotide polymorphisms’’
(SNPs), where commonly co-occurring SNPs form haplotypes.
Large-scale mutations, such as losses of DNA (deletions) or
duplications, can affect one ore multiple genes resulting in
‘‘copy-number variations’’ (CNVs), where there are fewer or
more copies of one or several genes on a chromosome. Variants
generally deemed suitable for the purposes of genetic imaging
have been selected on the basis of one or more of the following
criteria:
(1) Functional variants with a known neurochemical effect
(e.g., Val158Met substitution [rs4680] in the gene for
Catechol-O-Methyltransferase, COMT [Mier et al.,
2010]; long/short repeat [5-HTTLPR] in the promoter of
the SLC6A4 gene, which codes for the serotonin [5-HT]
transporter [Savitz and Drevets, 2009]).
(2) Common variants with small or medium contribution
to disease risk, supported by GWAS (e.g., ZNF804A
[Esslinger et al., 2009b] and CACNA1C [Erk et al., 2010]
for psychosis).
(3) Rare variants with large contribution to disease risk:
Williams syndrome (Meyer-Lindenberg et al., 2006);
velocardiofacial syndrome (Karayiorgou et al., 2010);
genes associated with familial AD, such as presenilin
(Ringman et al., 2011).
Imaging Functional Polymorphisms
A polymorphism is called ‘‘functional’’ when it has a known effect
on the function or abundance of the encoded protein, and
any change in brain structure or function compared to the
noncarriers is supposed to be effected by this neurochemical
alteration (which presupposes that groups are as well matched
as possible for other potential genetic or environmental differ-
ences). These genetic variants can thus serve as models for
long-term pharmacological effects.
In the case of the COMT gene, the carriers of the variant that
codes for methionine have lower enzyme activity and thus higher
synaptic dopamine levels because COMT is one of the main
catabolic enzymes for catecholamines. This genetic variant
has therefore been proposed as an endogenous model of dopa-
minergic activation, especially for areas lacking the dopaminetransporter. A recent meta-analysis of the imaging studies of
the COMT Val158Met SNP has yielded evidence for higher
prefrontal cortex (PFC) activation in carriers of the Met-allele
during emotion tasks, but higher activation in Val-allele carriers
during tasks probing executive control. This dissociation of
higher PFC activation, interpreted as indicating less efficient or
more noisy cortical activity, during cognitive and lower (more
efficient) activation during emotional tasks may explain why the
Val-allele seems to be associated with improved emotion
regulation but impaired cognitive control (Mier et al., 2010).
The interpretation of higher PFC activation as indicating impaired
signal-to-noise, although compatible with the behavioral data
and computational models of dopaminergic signaling in PFC
(Winterer and Weinberger, 2004), is speculative and would
have to be supported by recording from a behaving animal
model, where noise components of neural activation can be
identified more directly than in functional imaging (Gonzalez-
Burgos et al., 2005).
The short variant of the s/l polymorphism in the SLC6A4 gene
leads to lower transcription of the gene and thus to lower levels
of the serotonin transporter and higher levels of serotonin in the
synaptic cleft. It was associated with increased relative activa-
tion of the amygdala to negative compared to neutral affective
stimuli, an attentional bias toward negative material, and altered
connectivity between the amygdala and prefrontal areas in
several fMRI studies with healthy individuals and patients with
depression (Savitz and Drevets, 2009). Variants on several
other genes that are of interest to depression have also been
associated with altered amygdala activation on functional
imaging, although findings here have been less consistent
(Savitz and Drevets, 2009). These included a functional variable
number tandem repeat (VNTR) in the promoter of the mono-
amine-oxidase A gene that affects expression levels, a SNP
(rs4570625) without known function in the gene for tryptophan
hydroxylase-2, the rate-limiting enzyme for the synthesis of
5-HT in the raphe, and the BDNF Val66Met SNP (rs6265), which
results in protein variants with different rates of secretion (Egan
et al., 2003). The interest in BDNF (brain-derived neurotrophic
factor) has been fuelled by the emergence of the neurotrophic
theory of depression, which posits that reductions of hippo-
campal neurogenesis can lead to depressive phenotypes (at
least in animal models) that can then be reversed by neurotro-
phins (Krishnan and Nestler, 2010) and possibly by antidepres-
sants. An important aspect of genetic imaging, which is crucial
for its validation, is the potential for the study of homologies of
gene effects across species. For example the effects of the
BDNF Val66Met variants on structure and function of the human
hippocampus and on behavior can be compared with a Met/Met
homozygous mouse model (Chen et al., 2006), where neural
effects can be tested at much higher spatial and molecular reso-
lution.
Imaging Disease-Associated Genetic Variants Identified
by GWAS
Although imaging functional polymorphisms has yielded impor-
tant insights in the downstream effects of the genetic variants,
the clinical relevance of these loci is less clear. Although many
of them had initially been implicated in mental disorders through
candidate studies, genome-wide association studies (GWAS),Neuron 73, January 12, 2012 ª2012 Elsevier Inc. 15
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operate without specific underlying biological models, which
differentiates them from the candidate gene approach, have
brought up risk loci for psychiatric diseases about whose func-
tion little, if anything, was known.
Although the effects of the newly identified genome-wide
supported risk variants on protein structure and function will
ultimately only be answered by molecular and cell biology,
neuroimaging can provide global measures of the pathways
involved (Inkster et al., 2010). For example, several SNPs on
genes coding for subunits of the GABA-A receptor have been
associated with bipolar disorder, but they do not alter protein
sequence and their function is unknown (Craddock et al.,
2010). One possibility is that they affect the expression levels
of subunits and thus the functionality of the resulting GABA
receptors, which could be tested with noninvasive markers of
the GABA system derived from MEG and MRS (Muthukumar-
aswamy et al., 2009). This rationale is even more relevant for
the rare CNVs that are enriched in autism, mental retardation,
ADHD, schizophrenia, and possibly other mental disorders
(Owen et al., 2010; Williams et al., 2010). These CNVs are only
present in a small minority of cases and their immediate molec-
ular effects therefore unlikely to explain the pathophysiological
pathways underlying the disorder. However, many CNVs on
different genes may affect the same functional system—for
example NMDA receptor complexes in the case of schizophrenia
(Kirov et al., 2011)—and thus converge on intermediate
(neurobiological) phenotypes that can be mapped out with
noninvasive techniques (Figure 2). One example is the mismatch
negativity, a negative deflection of the event-related potential
that is evoked by deviants in trains of auditory stimuli and can
be modulated by antagonists of the NMDA receptor (Stephan
et al., 2006). Such a noninvasive index of a putative pathological
process might then become a proof-of-concept marker for inter-
vention studies.
The choice of biological target for potential gene effects can
be informed by endophenotypes, which are heritable traits that
can be defined at any level from biochemistry to behavior. In
order to meet the definition of an endophenotype for a particular
disease (Gottesman and Gould, 2003), a trait needs to occur in
both patients and unaffected relatives more frequently than
in the general population. The crucial idea is that endopheno-
types are more closely associated with specific genes than the
clinical phenotype and can aid in the discovery of new disease
genes or in the definition of genetic subtypes of the disease.
Several such endophenotypes have been proposed on the
basis of neuroimaging findings, for example, reduced GABA
concentrations asmeasured byMRS in relation to major depres-
sion (Hasler and Northoff, 2011). Intermediate phenotypes
derived from imaging can then be used both to refine the clinical
phenotype (moving upward on Figure 2) and to identify the
underlying biological and genetic pathways (moving downward
on Figure 2), with the ultimate aim of producing psychiatric
diagnoses with a firmer biological foundation and etiology.
For example, the psychosis risk allele on the ZNF804A gene
was associated with altered fronto-hippocampal connectivity
(Esslinger et al., 2009a), and the risk allele on the CACNA1C
gene with altered activation of the subgenual cingulate cortex16 Neuron 73, January 12, 2012 ª2012 Elsevier Inc.(Erk et al., 2010), which had previously been proposed as neural
correlates of schizophrenia and bipolar disorder, respectively
(see Figure 2).
Genetic Imaging: Critiques and limitations
The field of genetic imaging has grown considerably over the
last decade and has the attractive potential of bridging the gap
between human cognitive neuroscience and research at the
molecular level, but presently still faces important limitations.
Most research so far has only looked at effects of single genes
or even single loci, without applying the corrections for multiple
comparisons across the genome that have become the standard
for GWAS of clinical phenotypes. Although the choice of
the particular genetic variant can often be supported by bio-
logical plausibility or association with a clinical phenotype, this
approach makes the field vulnerable to false positive findings
(Bigos andWeinberger, 2010). Genome-wide correction of asso-
ciations with imaging phenotypes probably requires sample
sizes at least in the hundreds, and several multicenter studies
have now taken this approach, using single structural measures
such as hippocampal (Potkin et al., 2009a) or caudate (Stein
et al., 2011) volume or single functional measures such as frontal
activation during working memory (Potkin et al., 2009c) as quan-
titative traits. This approach also opens up the possibility to
discover new genetic variants that contribute to disease at least
in subgroups of patients, thus fulfilling the promise of the endo-
phenotype concept (Potkin et al., 2009b). However, success in
implementing such an approach depends fundamentally on the
quality of the selected imaging phenotype, and the replication
of association data for the same phenotype has not thus far
been successful (Potkin et al., 2009b, 2009c). The ideal scenario
would combine genome-wide strategies with brain-wide
imaging analyses. A recent study exemplifying this approach
implemented a GWAS for imaging phenotypes across the whole
brain in patients and controls from the Alzheimer’s Disease Neu-
roimaging Initiative (ADNI) (Shen et al., 2010). However, this
study employed parcellation of the brain into 142 subvolumes
and then conducted 142 parallel GWAS on these measures
and thus did not actually correct for the multiple phenotypes
across the brain. A study that did apply such whole-brain correc-
tion (using the false discovery rate) did not find genome-wide
significant association with brain structure in a sample of 731
participants from the ADNI cohort (Hibar et al., 2011b), although
their pooling of patients with AD and MCI and healthy elderly
controls may have decreased statistical power. Nevertheless it
is likely that, in order to obtain the power to enable multiple
comparison corrections with feasible sample sizes data reduc-
tion techniques will be mandatory. Various statistical techniques
have been proposed for the joint multivariate analysis of genetic
and imaging data (Hibar et al., 2011a; Vounou et al., 2010).
Another strategy to increase the power of genetic imaging
studies to detect clinical biomarkers would be to focus on vari-
ants of strong effect and high penetrance or to pool the effects
of multiple variants with small effect (across the whole genome
or across specific biological pathways) into polygenic risk scores
(Holmans, 2010). The downside of this approach is loss of
molecular resolution because polygenic scores integrate across
different genes (and thus proteins) and CNVs with higher pene-
trance are normally so rare that individuals with different variants
Figure 3. Activation of Left Primary Auditory
Cortex during Auditory Verbal Hallucinations
Activation of left primary auditory cortex during auditory
verbal hallucinations in a patient with schizophrenia
(a), compared with bilateral activation during verbal
stimulation (b). Reprinted from Dierks et al. (1999) with
permission.
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achieve sufficient group sizes for statistical analysis.
The area of genetic imaging has been criticized for reporting
unreasonably high effect sizes (or for claiming to find significant
genotype effects in samples much smaller than those needed in
clinical association studies). Estimates for the variance of
functional imaging signal explained by single genetic variants
have been up to 10% (for the 5-HTTLPR variant in relation to
amygdala activation to emotional stimuli; Munafo` et al., 2008).
Although the heritability of amygdala activation in humans is
unknown (a study in monkeys found heritability only for hippo-
campal but not amygdala glucose metabolism; Oler et al.,
2010), moderate heritability has been reported for functional
activation in other areas (Blokland et al., 2011). Moderate to
high heritabilities have also been reported for brain volume
measures from twin studies, although sample sizes were
generally small (Peper et al., 2007), and a larger cohort study
(Framingham Heart Study) found generally lower heritabilities
(e.g., 0.26 for the frontal lobe and 0.46 for total brain volume)
(DeStefano et al., 2009). Thus, the heritability of imaging pheno-
types is generally lower than that of the clinical phenotype (up to
0.8 for schizophrenia, for example; Sullivan et al., 2003).
Conversely, the effect sizes for associations between single
risk loci and imaging phenotypes have generally been much
higher than for those with the clinical phenotype. For example,
the putative schizophrenia risk variant on the gene for nitric
oxide synthase 1 (NOS1, rs6490121, reported in a GWAS by
O’Donovan et al. [2008] but not replicated in further studies) ex-
plained 9% of the variance of the amplitude of the P1 compo-
nent of the visual evoked potential (O’Donoghue et al., 2011),
which is more than the 6% variance of the clinical phenotype
explained by all significant variants collectively (Ripke et al.,
2011). The underlying model assumes that many different
combinations of genetic variants can contribute to the clinical
phenotype, which is why the effect of any single variant on
disease risk is very small, and that each gene can influence
a different biological pathway (Figure 2). Conversely, the
imaging endophenotype would be associated with fewer
genetic loci. Thus, even if the heritability of the endophenotype
is lower than that of the disease itself, its associations with
specific genes may be more easily detectable. The ultimateNetest will be whether these genetic imaging
associations replicate in independent samples.
Thus the main methodological challenge for
genetic imaging lies in protection against
false-positive findings. In addition to rigorous
corrections for multiple testing and replication
experiments the solution might involve registra-
tion of studies, similar to the proposals forclinical imaging in general, and depositing sets of primary
hypotheses.
Neural Correlates of States and Traits
Instead of trying to find biological correlates of complex clinical
phenotypes, a more basic approach may be to focus on specific
traits and states associated with particular mental disorders.
Whereas traits are habitual patterns of behavior, thought, and
emotion, states are temporary and are often elicited by identifi-
able stimuli or events. Thus, a mental disorder can be broken
down into its main symptoms or states and its associated
personality traits, and these can then be investigated separately
by means of neuroimaging. Because single psychological states
and traits may have clearer neural correlates than the complex
clinical phenotype, this approach could be more sensitive than
the comparison of diagnostic groups. However, this method
has so far not led to the identification of more specific
biomarkers or genetic loci of stronger effect than those associ-
ated with clinical diagnoses (Shifman et al., 2008). One possible
solution is to obtain personality measures from questionnaires
and correlate them with brain parameters that are supposed to
be reasonably constant over time, for example regional volume-
try, cortical thickness, or neurotransmitter concentrations
measured with MRS (Boy et al., 2011). This approach faces the
difficulty of finding reliable brain measures and correcting for
the often large number of statistical tests at the whole brain level.
The field is in many respects similar to that of genetic imaging
because only weak associations have been established between
single personality traits and mental disorder, and innovative
ways of combining them to risk measures are needed to identify
disease pathways with sufficient power.
More direct inroads into the neural basis of psychopathology
can be made by scanning patients during spontaneously occur-
ring or experimentally induced symptoms. For example, asking
patients suffering from auditory verbal hallucinations to report
the on- and offset of the voices during scanning allowed
researchers to obtain the associated neural activation patterns
from whole-brain correlation analysis (Dierks et al., 1999; Jardri
et al., 2011; Silbersweig et al., 1995) (Figure 3). One important
limitation of symptommapping is that the symptoms and indeed
their neural correlates may not discriminate well betweenuron 73, January 12, 2012 ª2012 Elsevier Inc. 17
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nations, activity in auditory cortex was observed both in patients
with schizophrenia and in nonclinical hallucinators who report
this isolated symptom, but without associated distress or
functional impairment (Linden et al., 2011). The strength of
symptom mapping thus seems to lie in its ability to detect neural
correlates of specific psychopathological states, which can
inform symptom-targeted treatments and aid in the monitoring
of clinical effects (Linden, 2006), but not in the elucidation of
antecedent causal mechanisms.
Nonpharmacological Treatment Strategies that Arise
from Neuroimaging
There are various ways in which such symptom or trait mapping
can be fruitful for translation. Multimodal imaging may reveal
correlations between cognitive processes or motivational states
and specific neurotransmitter systems, as shown for alcohol
craving and dopamine receptor availability in the ventral striatum
(Heinz et al., 2004). Functional imaging might also become a tool
to infer mental states from brain activation for diagnostic
purposes, although there are important ethical limitations to
such intrusions into privacy. In a less contentious application,
differences in imaging parameters might in the future help differ-
entiate patients more likely to respond to a specific treatment.
Functional neuroimaging of glucose and oxygen metabolism
with PET and fMRI has already been used in the monitoring of
pharmacotherapy, psychotherapy and cognitive interventions
(DeRubeis et al., 2008; Linden, 2006; Vyas et al., 2011), but not
yet yielded biomarkers that can assist in individual treatment
decisions.
Finally, functional imagingmight provide the basis for noninva-
sive or invasive therapies that specifically target the nodes and
networks identified by neuroimaging. Examples include
attempts at attenuating auditory hallucinations with TMS of the
temporal lobe or improving treatment-resistant depression with
deep-brain stimulation of the subgenual anterior cingulate cortex
(George and Aston-Jones, 2010; Hoffman et al., 2003; Mayberg
et al., 2005). One crucial methodological question for the devel-
opment of new nonpharmacological treatments is whether to
expect that treatment effects will only affect areas of primary
dysfunction. Some of the imaging studies of therapy effects,
for example in obsessive compulsive disorder, have indeed
shown normalization of altered metabolic patterns after both
psycho- and pharmacotherapy (Linden, 2006). Conversely, in
other disorders, notably depression, the link between brain
correlates of successful therapies and pre-existing brain
dysfunction is less straightforward (Krishnan and Nestler, 2010;
Linden, 2008). It is therefore conceivable that psychiatric treat-
ments operate through mechanisms other than normalization
of pathological brain networks, for example by activating
compensatory pathways.
Functional neuroimaging has been singularly successful at
identifying functional networks in humans. Most of clinical
imaging has tried to identify dysfunctions in these networks in
patient populations, and come up against the many difficulties
discussed in this review. By comparison, much less effort has
been spent trying to utilize the knowledge about these functional
networks for the remediation of cognitive, emotional, or behav-18 Neuron 73, January 12, 2012 ª2012 Elsevier Inc.ioral deficits. For example, a great deal is now known about
the neural systems involved in emotion regulation (Ochsner
and Gross, 2005; Phillips et al., 2008), and this information could
be used to train patients with mood disorders (Clark and Beck,
2010). Potentially testing this theory is becoming more tractable
with the advent of advanced neuroimaging techniques, particu-
larly real-time fMRI. With real-time feedback about their regional
brain activation, patients can be trained to regulate activity in
specific areas or networks, a procedure termed ‘‘neurofeed-
back’’ (deCharms, 2008; Johnston et al., 2010; Weiskopf et al.,
2003). In principle this provides the opportunity to influence
localized brain activation non-invasively in a way that is
controlled by the patients themselves and could allow them to
regulate dysfunctional networks or activate compensatory
pathways. fMRI-neurofeedback, targeting the anterior cingulate
cortex, has shown preliminary success in chronic pain in patients
with fibromyalgia (deCharms et al., 2005), and patients with
Parkinson’s disease may benefit from self-regulation of the
supplementary motor area (Subramanian et al., 2011). Ulti-
mately, though, any clinical application of neurofeedback and
other brain-based therapies in psychiatric disorders will have
to be integrated in a comprehensive biopsychosocial interven-
tion program.
Conclusions
Neuroimaging plays a critical role in psychiatry as it can poten-
tially be used to identify biomarkers of disease, prognosis, or
treatment, elucidate biological pathways, and help redefine
diagnostic boundaries and inform and monitor new therapies.
Although several imaging and electrophysiological features
have been consistently associated with mental disorders, none
of them has the required sensitivity and specificity to qualify as
a diagnostic marker. Promising results with low error rates for
diagnostic or prognostic applications have been obtained
through the use of multivariate classifier techniques, but these
have rarely been tested across laboratories and not been vali-
dated in larger patient samples. Directions in neuropsychiatric
imaging that appear promising transcend the constraints of the
currently defined diagnostic boundaries. Functional imaging of
genetic variants can be used to probe specific biological path-
ways associated with mental disorder and identify convergent
mechanisms for clusters of risk genes to provide biological
correlates of genetic load. A similar fractionation of mechanisms
that contribute to psychiatric diseases might be achieved by
state and trait mapping, based on psychopathological and
personality models. The ultimate hope is that the better under-
standing of the biological pathways to psychiatric disease will
result in the development of new treatments. The insight into
the neural mechanisms of psychiatric symptoms achieved
through neuroimaging has already informed new nonpharmaco-
logical interventions such as deep-brain stimulation, transcranial
magnetic stimulation, and neurofeedback that are currently in
clinical testing.
Early and prophylactic interventions present an emerging
future direction in clinical psychiatry (McGorry et al., 2011), and
neuroimaging has the potential to aid the identification of individ-
uals at risk and monitor the effects of these interventions. Future
aims in the development of surrogate treatment markers would
Neuron
Reviewinvolve assessing whether psychological or pharmacological
interventions normalize the patterns of brain structure or function
that predicted disease risk. Another future direction with consid-
erable clinical benefit would be the development of biomarkers
that predict the response to a particular treatment and could
then be used for therapeutic stratification. Despite available
imaging techniques (Table 1) and molecular targets (Table 2),
new ways of targeting intracellular processes are likely needed.
A key persisting question for imaging research in psychiatry with
respect to developing novel treatments is whether to focus on
the detection of the primary pathology, or whether to probe the
pathways that underlie resilience and recovery. There is thus
ample scope for ongoing and new psychiatric imaging initiatives
to establish biomarkers and targets for diagnostic and thera-
peutic applications.
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